[Radiotherapy of stage T1-T2 M0 prostatic adenocarcinoma. Analysis of the carcinologic results of a multicenter study of 610 patients. Groupe Radiothérapie de la Commission de Coopération Médicale Intercentres (CCMI)].
OBJECTIVE
Retrospective analysis of the results of radiotherapy in localized prostatic adenocarcinoma. Complications were excluded.


METHODS
Six-hundred-and-ten T1-T2 adenocarcinomas of the prostate were treated with continuous courses of external beam radiation therapy in 19 participating Institutes between January 1983 and January 1988. The mean follow-up was 10.4 years; the mean age of patients at the beginning of radiotherapy was 68.5 years.


RESULTS
A 10-year, local control had been achieved in 86% of T1-T2 (81.4% for T2). The 5- and 10-year metastatic relapse rates were 25.3% and 30% (29% and 38.1% for T2), respectively. At 10 years, 62.4% of T1-T2 were recurrence-free; overall survival rate was 45.8% and cause-specific survival rate was 70.5%; 29.9% of T1-T2 patients were alive and disease-free. T category (TNM), pathologic grade, pelvic lymph node status, local tumor control, and obstructive ureteral symptoms were correlated with survival. The influence of pelvic nodes radiation, dose, overall treatment time, previous endocrine treatment, and transuretral resection was not significant for disease-free survival (alive and disease-free) and other endpoints.


CONCLUSIONS
There was no difference between the French series (1975-1982 and 1983-1988). The results of the literature are comparable to ours. As far as prognostic factors are concerned, this report provides evidence that the explainable variables which influence survival depend on the tumor and patient status.
Département de radiothérapie et de chirurgie, centre régional de lutte contre le cancer Jean-Perrin, Clermont-Ferrand, France.
R
R
Rozan
E
E
Albuisson
B
B
Giraud
J P
JP
Boiteux
J
J
Dauplat
D
D
Donnarieix
L
L
Alcaraz
H
H
Auvray
Y M
YM
Allain
P P
PP
Duchatelard
J
J
Pigneux
P
P
Richaud
F
F
Bonichon
J M
JM
Bachaud
M
M
Hay
C
C
Chenal
V
V
Julienne
D
D
Brune
J J
JJ
Mace-Lesec'h
V
V
Beckendorf
P
P
Bey
F
F
Eschwege
D
D
Pontvert
M
M
Bolla
P
P
Rambert
D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D016019:Survival Analysis
D017430:Prostate-Specific Antigen
Radiothérapie de l'adénocarcinome prostatique de stade T1-T2 M0. Analyse des résultats carcinologiques d'une étude multicentrique de 610 patients. Groupe Radiothérapie de la Commission de Coopération Médicale Intercentres (CCMI).